Skincare

The acquisitions of the past two years are of brands that own a claim a buyer thinks it can defend. L'Oréal took a majority stake in Medik8 as a route into the fast-growing dermatological skincare market. Galderma agreed to buy ZO Skin Health for 1.5 billion, a physician-dispensed brand with roughly 330 million in net sales, sold through more than 16,500 physician, medical spa and online accounts in over 40 countries. Bridgepoint bought Obagi Medical for up to $460 million, naming its scientific heritage and physician relationships, and calling physician-dispensed skincare one of the fastest-growing segments of dermatology and aesthetics. Hindustan Unilever paid about $350 million for Minimalist, an actives-led digital brand, and Wipro bought into Dermatouch for its science-led direct-to-consumer position. Henkel took Olaplex and Estée Lauder took a stake in 111Skin in the same half-year.

Across otherwise unrelated payloads, the engineering has moved to what carries the active. P&G claims polymer capsules defined by a burst-strength range and a shell between roughly 20 and 400 nm. Givaudan files a family of core-shell microcapsules built around a hydrated polymer phase and an aminosilane interface. Tagra builds multi-layer microcapsules for vitamin C and rutin specifically. A university group reports a Pickering system encapsulating idebenone, psoralen and squalane above 90% efficiency. A polymer carrier is claimed for raising retention of a volatile active on skin, with the carrier itself as the product. The same problem is solved repeatedly by applicants who do not otherwise compete, which is the clearest statement in the filings about where they think value sits.

A second line drops surfactant molecules altogether and stabilises the interface with particles. Microcrystalline cellulose with a Sphingomonas fermentation extract and a lysate does the job for sensitive skin. Plant and mineral particles follow: green-thorn pomace powder, broken-cell-wall pine pollen, surface-modified volcanic mud, and halloysite nanotubes electrostatically paired with fucose and chitosan.

The compliance surface widened on several fronts at once. In the US, MoCRA's registration and listing obligations set deadlines for facilities and products, and a certification standard was introduced specifically to give finished products defined safety-substantiation benchmarks aligned to it. The EU capped retinol concentrations in facial and body products. India's drug regulator cancelled registrations for products above its salicylic acid limit, and Vietnam suspended 162 products for failing to produce product information files.

The device filings concentrate on the interface that ties a refill to its seller. Hironic claims a handpiece that reads a cartridge's unique number and activation status and tracks an operation count against a limit. Dimi Life claims a consumable unit whose chip stores consumable information and preset care modes, with the control unit managing extrusion order, timing and quantity. L'Oréal claims a system that selects and mixes booster and base compositions from user input and skin analysis. A microcapsule release device bursts its capsules as the solution flows past a heating element. The one registered trial in the area runs a home device with no cartridge or pump described. The effort is going into the lock between device and refill, not into showing the metered dose does anything a fixed dose would not.

The actives worth carrying are the ones that misbehave. Ceramides precipitate, and the formulation literature is explicit that undissolved ceramide is counterproductive to barrier repair. Salicylic acid recrystallises. CBD is stubbornly lipophilic. The answers are encapsulation, inclusion complexes and solvent systems tuned to stop precipitation: glabridin wrapped in a self-assembled lipid bilayer under 150 nm, dextrin esters synthesised at a controlled degree of substitution to act as oil-in-water emulsifiers, a Pickering emulsion whose stated purpose is to keep plant vesicle structures from degrading, and microcapsules with a solid polymer shell around an oil core.

Bemotrizinol entered the US market in June 2026 as the first new UV filter cleared in more than twenty years, and Neutrogena put it into two facial sunscreens within months. It reached the shelf as an over-the-counter drug ingredient, with a concentration limit and a monograph behind it, not as a cosmetic active. That is the only route by which a genuinely new molecule has entered this market in the period, and it is the route the composition work does not take. A New Zealand brand treats its US over-the-counter registration as the asset that opens pharmacy distribution.